Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke | Zendy

Paul A. Lapchak | Zendy; Deborah F. Chapman | Zendy; Justin A. Zivin | Zendy

Open Access

Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke

Author(s) -

Paul A. Lapchak,

Deborah F. Chapman,

Justin A. Zivin

Publication year - 2000

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.31.12.3034

Subject(s) - medicine , tissue plasminogen activator , embolization , intracerebral hemorrhage , plasminogen activator , fibrin , stroke (engine) , middle cerebral artery , ischemia , anesthesia , surgery , subarachnoid hemorrhage , immunology , mechanical engineering , engineering

A potentially dangerous side effect associated with tissue plasminogen activator (tPA) use is cerebral hemorrhage. We have focused on developing drugs that could be administered with tPA to reduce the rate of hemorrhage. Since recent studies suggest that various matrix metalloproteinases (MMPs) are important in tumor necrosis factor-alpha production and membrane and vessel remodeling after ischemia, we investigated whether MMP inhibition affected the rate of hemorrhage and infarct production in the absence or presence of tPA treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research